查詢結果分析
來源資料
相關文獻
- 臺灣市售易誤用、混用中藥品種之檢討(2)
- 板藍根藥材之鑑別研究
- 臺灣市售易誤用、混用中藥品種之檢討(3)
- 靛藍及靛玉紅鎮痛及抗發炎作用之研究
- 預防SARS生藥--板藍根
- 以細胞株培養、小白鼠模式、及臨床試驗方式做有系統探討及比較中西方天然草本製劑對抗病毒感染及增加免疫功能之效用:細胞層級的試驗(2-2)
- 以細胞株培養、小白鼠模式、及臨床試驗方式做有系統探討及比較中西方天然草本製劑對抗病毒感染及增加免疫功能之效用:細胞層級的試驗(全程總報告)
- 飼糧添加板藍根複方中藥草對土雞生長性能及免疫反應之影響
- 認識常用中藥--板藍根
- 以細胞株培養、小白鼠模式、及臨床試驗方式做有系統探討及比較中西方天然草本 製劑對抗病毒感染及增加免疫功能之效 用:細胞層級的試驗(2-1)
頁籤選單縮合
題 名 | 臺灣市售易誤用、混用中藥品種之檢討(2)=Studies on the Commonly Misused, Adulterated Chinese Crude Drug Species in Taiwan(Ⅱ) |
---|---|
作 者 | 張永勳; | 書刊名 | 中醫藥年報 |
卷 期 | 16:2 1998.05[民87.05] |
頁 次 | 頁481-519 |
分類號 | 414.33 |
關鍵詞 | 板藍根; 大青葉; 青黛; 顯微鑑別; 化學鑑別; 方劑用藥統一; Ban-lan-gen; Da-ching-yeh; Ching-dai; Microscopic identification; Chemical identification; Unification of the species used; |
語 文 | 中文(Chinese) |
中文摘要 | 本年繼續進行臺灣市售易混用、誤用中藥品種之檢討,以板藍 根、大青葉及青黛等藥材為對象,進行(1)各種市售板藍根、大青葉 及青黛市場品之收集;(2)文獻調查:本草考察、藥用植物學考察、 化學成分考察、藥理及臨床應用文獻考察;(3)臺灣本產板藍根、大 青葉及青黛植物之收集;(4)顯微鑑別;(5)化學鑑別:以TLC及HPLC 與指標成分作定性定量比對;(6)市售含板藍根、大青葉及青黛中藥 方劑製劑中,板藍根、 大青葉及青黛藥材選用調查;(7)對各種市售 板藍根、大青葉及青黛進行藥理活性評估比較;(8)利用現有化學、 藥理、臨床等文獻資料及本實驗所作藥理活性評估結果,依各成方 方劑之臨床主治,對該方中應使用之板藍根、大青葉及青黛種類 加以建議統一;以期對此三類藥材作有系統之分析,提供中醫界、 中藥界及各中藥廠參考,做到「藥知病用,醫知藥情」,以達到全 面提昇中藥品質之理想。 研究結果顯示臺灣市售板藍根及大青葉經調查鑑定大部分為馬 藍(Baphicacanthus cusia (Nees) Bremek.)之根及葉,大陸藥典所收 載之菘藍(Isatis indigotica Fort.)之根及葉則未見使用。而臺灣 市售青黛大多以藍色色素充當,二十種僅有四種含靛玉紅(indirubin) 及靛藍(indigo)(兩種大陸、一種馬來西亞);而市售含青黛製劑-- 當歸龍薈丸中皆含靛玉紅(indirubin)及靛藍(indigo),黛蛤散中亦 含靛玉紅(indirubin)及靛藍(indigo)。青黛之青偽將直接影響臨床 療效,因此有必要對市售青黛及含青黛之製劑作全面之評估。 |
英文摘要 | In continuation of our five year project on the investigation of the commonly misused Chinese crude drugs species in Taiwan, we studied Ban-Lan-Gen (Isatidis Radix), Da-Ching-Yeh (Isatidis Folium) and Ching-Dai (Indigo Naturalis). Each of the three crude were investigated in the following aspects: 1)Various commercially available samples of the three drugs were collected. 2)Literature search on Pentsaology, medicinal plants, chemical components, pharmacological activities and clinical efficacy of the three herbs were carried out. 3)Native species of Ban-Lan-Gen and Ta-Ching-Yeh were collected and compared. 4)Microscopic examination of the Ban-Lan-Gen and Ta-Ching-Yeh were performed for identification. 5)Chemical identification of the three species using TLC and HPLC in comparison with indigo and indirubin were made. 6)Investigation on the patterns of Ban-Lan-Gen, Da-Ching-Yeh and Ching-Dai used in various compound formula containing those three drugs in the major GMP herbal pharmaceutical factories were studied by inquiry and reconfirmed by TLC analysis. 7)LD�tand antiinflammatory, analgesic activities of the various commercially available samples of the three species were compared. 8)Based on the initial indications of the prescriptions containing Ban-Lan-Gen, Da-Ching-Yeh and Ching-Dai and the current available literature together with the biological acivities evaluated in this study, the best suitable species of the three drugs were recommended. The results showed that the origin of Ban-Lan-Gen and Da- Ching-Yeh in Taiwan were identified as the root and leaves of Baphicacanthus cusia (Nees) Bremek. The species Isatis indigotica Fort. listed in the Pharmacopeia of PRC were not found in Taiwan. Most of the Ching-Dai used in Taiwan were found to be dyes, no indigo and indirubin were found in most of the samples. The commercial preparation, Dan-Kuei-Lung-Huei-Wan was found to contain indigo and indirubin. The identity of Ching-Dai will directly influence the clinical efficacy of the durg. Therefore, a comprehensive investigation of the quality of Ching-Dai should be carried out. |
本系統中英文摘要資訊取自各篇刊載內容。